Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory Diffuse Large B Cell Lymphoma”

539 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 539 results

Large-scale testing (Phase 3)Study completedNCT04182204
What this trial is testing

Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 270
Testing effectiveness (Phase 2)UnknownNCT04502394
What this trial is testing

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Who this might be right for
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon Hodgkin Lymphoma
Kartos Therapeutics, Inc. 84
Testing effectiveness (Phase 2)WithdrawnNCT05966233
What this trial is testing

R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma RefractoryDiffuse Large B-cell Lymphoma Recurrent
Fondazione Italiana Linfomi - ETS
Early research (Phase 1)Ended earlyNCT03558750
What this trial is testing

Rituximab, Lenalidomide, and Nivolumab in Treating Participants With Relapsed or Refractory Non-Germinal Center Type Diffuse Large B Cell Lymphoma or Primary Central Nervous System Lymphoma

Who this might be right for
Recurrent Central Nervous System LymphomaRecurrent Diffuse Large B-Cell LymphomaRefractory Central Nervous System Lymphoma+1 more
Vanderbilt-Ingram Cancer Center 6
Early research (Phase 1)Not Yet RecruitingNCT07113496
What this trial is testing

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Who this might be right for
Relapsed or Refractory B-cell Hematologic MalignanciesB-cell Acute Lymphoblastic Leukemia (B-ALL)Multiple Myeloma (MM)+3 more
The First Affiliated Hospital with Nanjing Medical University 27
Testing effectiveness (Phase 2)Study completedNCT00006125
What this trial is testing

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Alliance for Clinical Trials in Oncology
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics 86
Large-scale testing (Phase 3)UnknownNCT00003924
What this trial is testing

Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Lymphoma Study Association 360
Testing effectiveness (Phase 2)WithdrawnNCT02623920
What this trial is testing

Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaMediastinal Large B-cell LymphomaGrey Zone Lymphoma+4 more
University of Arizona
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Testing effectiveness (Phase 2)Study completedNCT01177371
What this trial is testing

High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+70 more
Case Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)Study completedNCT01030900
What this trial is testing

Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas

Who this might be right for
Hodgkin LymphomaDiffuse Large B-Cell Lymphoma
National Cancer Institute (NCI) 50
Early research (Phase 1)Study completedNCT00791011
What this trial is testing

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Who this might be right for
Hodgkin's LymphomaLow Grade LymphomaLymphoma+3 more
Amgen 33
Testing effectiveness (Phase 2)Ended earlyNCT03123393
What this trial is testing

TAK-659 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Who this might be right for
Diffuse Large B-cell Lymphoma
Calithera Biosciences, Inc 49
Testing effectiveness (Phase 2)Ended earlyNCT05626322
What this trial is testing

Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 6
Early research (Phase 1)Study completedNCT02549651
What this trial is testing

MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Who this might be right for
Diffuse Large B-Cell Lymphoma
MedImmune LLC 32
Testing effectiveness (Phase 2)Study completedNCT00867529
What this trial is testing

Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaB-cell Chronic Lymphocytic Leukemia+35 more
Fred Hutchinson Cancer Center 63
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Early research (Phase 1)Study completedNCT03340766
What this trial is testing

Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Who this might be right for
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Amgen 31
Load More Results